# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001576885-25-000057
Filing Date
2025-04-23
Accepted
2025-04-23 16:23:13
Documents
17
Period of Report
2025-06-04

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | abos-20250422.htm iXBRL | DEF 14A | 513775
3 |  | abos-20250422_g1.jpg | GRAPHIC | 27597
4 |  | abos-20250422_g2.jpg | GRAPHIC | 7937
5 |  | abos-20250422_g3.jpg | GRAPHIC | 3176
6 |  | abos-20250422_g4.jpg | GRAPHIC | 196435
7 |  | abos-20250422_g5.jpg | GRAPHIC | 105116
| Complete submission text file | 0001576885-25-000057.txt |  | 1657442

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | abos-20250422.xsd | EX-101.SCH | 930
19 | EXTRACTED XBRL INSTANCE DOCUMENT | abos-20250422_htm.xml | XML | 3179

Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40551 | Film No.: 25861823
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)